New Innovations in Heart Failure. Today We’ve invited two of Ohio State University’s cardiovascular experts to take us through the new therapies available to our heart failure patients and the practice changing guidelines to help us provide the best care to our patients. First, we have Heart Failure Cardiologist and Assistant Professor of Internal Medicine Dr Ajay Vallakati. Ajay specializes in Cardiac Amyloidosis. Second, we have Dr Indra Bole who is also an Assistant Professor of Internal Medicine and Heart Failure trained Cardiologist. His clinical interests are focused on cardiogenic shock, mechanical circulatory support, and heart transplant.
What you’ll learn in this webcast
As a result of this educational activity, webcast participants will be able to:
- Discuss pharmacological management of heart failure
- Recognize new heart failure therapies focusing on ivabradine, sacubitril-valsartan, and SGLT2i
- Understand the benefit of SGTL2i in the population of patients with heart failure with reduced ejection fraction
- Understand the benefit of SGTL2i in the population of patients with heart failure with preserved ejection fraction
You’ll also learn about the following:
- Heart Failure Classification
- Mortality
- Goal Directed Medical Therapy
- Advanced Therapies in Heart Failure
You can find this and many other MedNet21 programs on the OSU – CCME website.
Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.